Teva Pharmaceutical Industries (TEVA) closed at $42.61 on November 6, 2026, up 2.0% from the previous close, on volume of 5,084,874 shares (30-day average 6,621,320).
Data as of November 6, 2026.
J.P. Morgan Sticks to Their Buy Rating for Teva (TEVA)
TipRanks (Thu, 5-Nov 4:15 AM ET)
Teva’s Strong Execution and Growth Momentum Drive Buy Rating as Price Target Rises to $54
TipRanks (Wed, 4-Nov 8:15 AM ET)
Teva (TEVA) Gets a Buy from Scotiabank
TipRanks (Wed, 4-Nov 4:26 AM ET)
Teva Earnings Call Signals Stronger Growth Ahead
TipRanks (Tue, 3-Nov 7:19 PM ET)
Teva to buy U.S. rights to two Samsung Bioepis biosimilars
Seeking Alpha News (Tue, 3-Nov 9:16 AM ET)
Teva raises 2026 outlook on strength of innovative brands
Seeking Alpha News (Tue, 3-Nov 7:58 AM ET)
Teva raises 2026 outlook for AUSTEDO, AJOVY and UZEDY after strong Q3 growth
Seeking Alpha News (Tue, 3-Nov 7:24 AM ET)
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
Globe Newswire (Tue, 3-Nov 5:00 AM ET)
Teva Pharmaceutical Industries Limited Q3 2026 Earnings Preview
Seeking Alpha News (Mon, 2-Nov 10:02 AM ET)
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Teva Pharmaceutical Industries trades on the NYSE stock market under the symbol TEVA.
As of November 6, 2026, TEVA stock price climbed to $42.61 with 5,084,874 million shares trading.
TEVA has a beta of 0.97, meaning it tends to be less sensitive to market movements. TEVA has a correlation of 0.08 to the broad based SPY ETF.
TEVA has a market cap of $49.70 billion. This is considered a Large Cap stock.
Last quarter Teva Pharmaceutical Industries reported $4 billion in Revenue and $.86 earnings per share. This beat revenue expectation by $146 million and exceeded earnings estimates by $.14.
In the last 3 years, TEVA traded as high as $43.34 and as low as $8.55.
The top ETF exchange traded funds that TEVA belongs to (by Net Assets): IEFA, EFA, EIS, EFG, IXUS.
TEVA has outperformed the market in the last year with a price return of +73.2% while the SPY ETF gained +9.6%. TEVA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +22.7% and +6.0%, respectively, while the SPY returned -4.2% and -3.8%, respectively.
TEVA support price is $40.94 and resistance is $42.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TEVA shares will trade within this expected range on the day.
